Examining Patient Preferences About the IBM Watson Oncology Clinical Decision Support System

Breast Cancer Clinical Trial

Official title:

Examining Patient Preferences About the IBM Watson Oncology Clinical Decision Support System

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02565017
• Other study ID #: 15-226
• Status: Completed
• Start date: September 15, 2015
• Est. completion date: June 22, 2020

Study information

• Verified date: August 2019
• Source: Memorial Sloan Kettering Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to learn what cancer patients think about IBM Watson Oncology. IBM Watson Oncology is a computer program designed to help inform oncologists about the best chemotherapy choices for their patients. The investigators will conduct focus groups with cancer patients who have received chemotherapy treatment at MSK in order to understand cancer patients' thoughts about IBM Watson Oncology.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 70
• Est. completion date: June 22, 2020
• Est. primary completion date: June 22, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• MSKCC patient 18 years or older

• Breast, lung, or colorectal cancer MSK patient as per EMR or clinician judgment having either:

• Chemotherapeutic adjuvant or neoadjuvant treatment with the first chemo visit occurring within the past 8 months and primary treatment (i.e., surgery), occurring within the past 6 months)at MSK

• OR chemotherapeutic treatment for metastatic disease with the first chemo visit occurring within the past 8 months at MSK

• OR chemotherapeutic treatment through an on-going MSK clinical trial as per clinician

• Residing in New York metro-area

Exclusion Criteria:

• Non-English speakers because we do not have the resources to conduct and translate the focus groups into other languages

• Patients who are not or will not receive their cancer care at MSKCC.

• Patient unwilling or unable to provide informed consent

Related Conditions & MeSH terms

• Breast Cancer
• Colorectal Cancer
• Colorectal Neoplasms
• Lung Cancer

Intervention

Behavioral:
• Focus groups
After the presentation of the of IBM Watson Oncology at the opening of the focus group, participants will be asked to fill out a de-identified brief 15-item questionnaire to assess participants' first impressions of IBM Watson Oncology. The questionnaire will be self administered, and will take approximately 5 minutes to complete. Completed questionnaires will be collected by a member of the study staff, and the focus group will proceed with introductions. The focus group will be audio recorded from the completion of the introductions and notes will be taken. The focus group guide will address the study aims. At the end of the focus group, participants will complete a 7-item questionnaire to capture simple demographic information including education, income, and health literacy. This questionnaire will take 3-5 minutes to complete.

Locations

Country	Name	City	State
United States	Memorial Sloan Kettering Cancer Center	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Acceptability of IBM Watson Oncology	Data collected through the brief questionnaires (e.g.,initial impressions of IBM Watson Oncology, sociodemographics) will be entered into an SPSS data file on the secure MSK server.	1 year

External Links

•   Memorial Sloan Kettering Cancer Center